Latest Richard I. Morimoto Stories
People diagnosed with Huntington's disease, most in their mid-thirties and forties, face a devastating prognosis: complete mental, physical, and behavioral decline within two decades.
The National Institutes of Health (NIH) has chosen two leading aging researchers at Albert Einstein College of Medicine of Yeshiva University to chair panels at the first symposium on "geroscience"—the study of how aging influences the onset of chronic diseases.
A group of researchers led by the Institute of Biotechnology and Biomedicine (IBB) and Universitat Autònoma de Barcelona (UAB) have achieved to quantify with precision the effect of protein aggregation on cell aging processes using as models the Escherichia coli bacteria and the molecule which triggers Alzheimer's disease.
Two related studies from Northwestern University offer new strategies for tackling the challenges of preventing and treating diseases of protein folding, such as Alzheimer's, Parkinson's and Huntington's diseases, amyotrophic lateral sclerosis (ALS), cancer, cystic fibrosis and type 2 diabetes.
Scientists at Northwestern University report a surprising discovery that offers a possible new route for the treatment of neurodegenerative diseases.
Like yoga for office drones, cells do have coping strategies for stress. Heat, lack of nutrients, oxygen radicals â€“ all can wreak havoc on the delicate internal components of a cell, potentially damaging it beyond repair.
People everywhere are feeling the stress of a worldwide recession. Our cells, too, are under continual assault from stress.
Proteostasis Therapeutics, Inc. (PTI) today announced that it has secured $45 million in a Series A financing to develop Proteostasis Regulator(TM) drugs as novel therapies to treat multiple genetic and degenerative disorders associated with protein homeostasis deficiencies.
- Large; stout; burly.